-
公开(公告)号：US5753631A
公开(公告)日：1998-05-19
申请号：US457886
申请日：1995-05-31
IPC分类号： A61K9/127 , A61K31/70 , A61K31/715 , A61K35/12 , A61K38/13 , A61K47/48 , C07H3/06 , C07H15/04 , C07H15/10 , C07K16/18 , C12N9/10 , G01N33/569 , C07H15/00
CPC分类号： C07H15/10 , A61K31/70 , A61K31/715 , A61K47/48023 , A61K47/48046 , A61K47/48092 , A61K47/48546 , A61K47/48815 , A61K9/1271 , C07H15/04 , C07H3/06 , C07K16/18 , C12N9/1051 , G01N33/56972
摘要： The present invention is directed towards compositions and methods for reducing or controlling inflammation and for treating inflammatory disease processes and other pathological conditions mediated by intercellular adhesion. The compositions of the invention include compounds that selectively bind selectin receptors, the selectin binding activity being mediated by a carbohydrate moiety. The selectin-binding moieties of the invention are derivatives of a sialylated, fucosylated N-acetyllactosamine unit of the Lewis X antigen. Compounds containing a selectin-binding moiety in both monovalent and multivalent forms are included in the invention. The compounds of the invention are provided as pharmaceutical compositions which include, for example, liposomes that carry selectin-binding moieties of the invention. The invention further includes immunoglobulins capable of selectively binding an oligosaccharide ligand that is recognized by a selectin receptor.
摘要翻译： 本发明涉及用于减少或控制炎症和治疗由细胞间粘附介导的炎性疾病过程和其它病理状况的组合物和方法。 本发明的组合物包括选择性结合选择素受体的选择素结合活性由碳水化合物部分介导的化合物。 本发明的选择素结合部分是Lewis X抗原的唾液酸化，岩藻糖化N-乙酰基乳糖胺单元的衍生物。 包含单价和多价形式的选择蛋白结合部分的化合物包括在本发明中。 本发明的化合物作为药物组合物提供，其包括例如携带本发明选择蛋白结合部分的脂质体。 本发明还包括能够选择性结合由选择素受体识别的寡糖配体的免疫球蛋白。
-
公开(公告)号：US07402307B2
公开(公告)日：2008-07-22
申请号：US10208243
申请日：2002-07-30
申请人： Federico C. A. Gaeta
发明人： Federico C. A. Gaeta
CPC分类号： C12N9/1241 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/55522 , C12N9/1276
摘要： The invention provides a method for activating a T lymphocyte by contacting the T lymphocyte with a dendritic cell (DC) that presents a telomerase reverse transcriptase (TRT) peptide in the context of an MHC class I or MHC class II molecule. The DC may be pulsed with a TRT polypeptide or may comprise a recombinant polynucleotide encoding a TRT such as hTRT. The invention also provides DCs comprising a recombinant TRT polynucleotide. The methods and compositions of the invention are used in prevention and treatment of cancers and other cell proliferation diseases or conditions.
摘要翻译： 本发明提供了通过使T淋巴细胞与MHC I类或II类分子的上下文中呈现端粒酶逆转录酶（TRT）肽的树突状细胞（DC）接触来激活T淋巴细胞的方法。 DC可以用TRT多肽脉冲，或者可以包含编码TRT的重组多核苷酸，例如hTRT。 本发明还提供了包含重组TRT多核苷酸的DC。 本发明的方法和组合物用于预防和治疗癌症和其它细胞增殖疾病或病症。
-
公开(公告)号：US5821231A
公开(公告)日：1998-10-13
申请号：US461056
申请日：1995-06-05
IPC分类号： A61K38/00 , A61K38/06 , A61K38/07 , A61K38/08 , A61P11/00 , A61P17/00 , A61P25/00 , A61P29/00 , C07K5/02 , C07K5/06 , C07K5/072 , C07K5/08 , C07K5/083 , C07K5/087 , C07K5/09 , C07K5/093 , C07K5/097 , C07K5/10 , C07K5/103 , C07K5/107 , C07K5/11 , C07K7/06 , C07K14/78 , A61K38/05 , C07K5/04
CPC分类号： C07K7/06 , C07K14/78 , C07K5/0205 , C07K5/0207 , C07K5/021 , C07K5/06034 , C07K5/06113 , C07K5/0804 , C07K5/0808 , C07K5/081 , C07K5/0812 , C07K5/0815 , C07K5/0819 , C07K5/0821 , C07K5/1005 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1019 , A61K38/00
摘要： The present invention contemplates a compound defined by the following formula: ##STR1## that inhibits the binding between the VLA-4 and the fibronectin CS-1 compound. Pharmaceutical compositions containing a contemplated compound and methods for treating immunoinflammatory conditions using the compound are also disclosed.
摘要翻译： 本发明涉及由下式限定的化合物：抑制VLA-4与纤连蛋白CS-1化合物之间结合的“IMAGE”。 还公开了含有预期化合物的药物组合物和使用该化合物治疗免疫炎性病症的方法。
-
公开(公告)号：US5679640A
公开(公告)日：1997-10-21
申请号：US400781
申请日：1995-03-08
申请人： Federico C. A. Gaeta , Michael F. Powell , Howard M. Grey , Alessandro D. Sette , Thomas S. Arrhenius
发明人： Federico C. A. Gaeta , Michael F. Powell , Howard M. Grey , Alessandro D. Sette , Thomas S. Arrhenius
CPC分类号： C07K7/08 , C07K14/005 , A61K38/00 , C12N2760/16022
摘要： Peptide compositions are provided which bind MHC molecules of interest and inhibit T cell activation. The peptide compositions of the present invention comprise various isosteres of naturally occurring amino acid sequences. Such compositions may be used to treat diseases associated with particular DR alleles, including autoimmune diseases such as rheumatoid arthritis.
摘要翻译： 提供了结合感兴趣的MHC分子并抑制T细胞活化的肽组合物。 本发明的肽组合物包含天然存在的氨基酸序列的各种等位基因。 这样的组合物可用于治疗与特定DR等位基因相关的疾病，包括自身免疫性疾病如类风湿性关节炎。
-
公开(公告)号：US4885293A
公开(公告)日：1989-12-05
申请号：US892003
申请日：1986-07-30
IPC分类号： A61K31/573 , A61K38/00 , C07D417/12 , C07K5/02
CPC分类号： C07D417/12 , C07C255/00 , C07K5/0222 , A61K38/00 , Y10S514/913
摘要： Pharmaceutical compositions and a method for reducing intraocular pressure by topically applying a carboxyalkyl dipeptide are disclosed.
摘要翻译： 公开了药物组合物和通过局部施用羧烷基二肽降低眼内压的方法。
-
公开(公告)号：US4826816A
公开(公告)日：1989-05-02
申请号：US784000
申请日：1985-10-04
IPC分类号： A61K38/00 , C07D285/26 , C07D417/12 , C07K5/02 , A61K37/00 , A61K31/54 , C07D279/00 , C07D285/00
CPC分类号： C07D417/12 , C07C255/00 , C07K5/0222 , A61K38/00 , Y10S530/80
摘要： Antihypertensive compounds with angiotensin-converting enzyme inhibitory activity and diuretic activity are disclosed. Such compounds are useful in the treatment of cardiovascular disorders, especially hypertension and congestive heart failure, and are useful in the treatment of glaucoma.
摘要翻译： 公开了具有血管紧张素转换酶抑制活性和利尿活性的抗高血压化合物。 这些化合物可用于治疗心血管疾病，特别是高血压和充血性心力衰竭，并且可用于治疗青光眼。
-
公开(公告)号：US07824849B2
公开(公告)日：2010-11-02
申请号：US11413838
申请日：2006-04-27
申请人： Federico C. A. Gaeta
发明人： Federico C. A. Gaeta
IPC分类号： C12Q1/00
CPC分类号： C12N9/1241 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/55522 , C12N9/1276
摘要： The invention provides dendritic cell (DC) preparations that present a telomerase reverse transcriptase (TRT) peptide in the context of an MHC class I or MHC class II molecule. The DCs may be pulsed with a TRT polypeptide, or may comprise a recombinant polynucleotide encoding TRT. The invention also describes the use of such compositions for the prevention and treatment of cancers and other diseases.
摘要翻译： 本发明提供了在MHC I类或II类分子的上下文中提供端粒酶逆转录酶（TRT）肽的树突状细胞（DC）制剂。 DC可以用TRT多肽脉冲，或者可以包含编码TRT的重组多核苷酸。 本发明还描述了这种组合物用于预防和治疗癌症和其它疾病的用途。
-
8.发明授权Method for screening an agent that modulates activity of macrophage migration inhibitory factor 失效筛选调节巨噬细胞迁移抑制因子活性的试剂的方法公开(公告)号：US07514225B2
公开(公告)日：2009-04-07
申请号：US11182360
申请日：2005-07-15
申请人： Federico C. A. Gaeta , Andrew Baird , Jerry Anchin , Wenbin Ying , Robert Florkiewicz , Jagadish Sircar , Sunil Kumar K. C.
发明人： Federico C. A. Gaeta , Andrew Baird , Jerry Anchin , Wenbin Ying , Robert Florkiewicz , Jagadish Sircar , Sunil Kumar K. C.
CPC分类号： C07D401/12 , C07D215/42 , C07D215/54 , C07D405/12 , C07D409/12
摘要： Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
摘要翻译： 提供了MIF的抑制剂，其可用于治疗各种疾病，包括治疗与MIF活性相关的病理状况。 MIF的抑制剂具有以下结构：包括其立体异构体，前药和药学上可接受的盐，其中n，R 1，R 2，R 3，R 4，X，Y和Z如本文所定义。 还提供了含有与药学上可接受的载体组合的MIF抑制剂的组合物，以及使用该组合物的方法。
-
9.发明授权公开(公告)号：US07432374B2
公开(公告)日：2008-10-07
申请号：US11687611
申请日：2007-03-16
申请人： Federico C. A. Gaeta , Andrew Baird , Jerry Anchin , Wenbin Ying , Robert Florkiewicz , Jagadish Sircar , Sunil Kumar K. C.
发明人： Federico C. A. Gaeta , Andrew Baird , Jerry Anchin , Wenbin Ying , Robert Florkiewicz , Jagadish Sircar , Sunil Kumar K. C.
IPC分类号： C07D215/42 , C07D215/54 , C07D401/06 , C07D403/06
CPC分类号： C07D401/12 , C07D215/42 , C07D215/54 , C07D405/12 , C07D409/12
摘要： Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
摘要翻译： 提供了MIF的抑制剂，其可用于治疗各种疾病，包括治疗与MIF活性相关的病理状况。 MIF的抑制剂具有以下结构：包括其立体异构体，前药和药学上可接受的盐，其中n，R 1，R 2，R 3， >，R 4，X，Y和Z如本文所定义。 还提供了含有与药学上可接受的载体组合的MIF抑制剂的组合物，以及使用该组合物的方法。
-
10.发明授权公开(公告)号：US07202248B2
公开(公告)日：2007-04-10
申请号：US11344938
申请日：2006-01-31
申请人： Federico C. A. Gaeta , Andrew Baird , Jerry Anchin , Wenbin Ying , Robert Florkiewicz , Jagadish Sircar , Sunil Kumar K. C.
发明人： Federico C. A. Gaeta , Andrew Baird , Jerry Anchin , Wenbin Ying , Robert Florkiewicz , Jagadish Sircar , Sunil Kumar K. C.
IPC分类号： A61K31/496
CPC分类号： C07D401/12 , C07D215/42 , C07D215/54 , C07D405/12 , C07D409/12
摘要： Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
摘要翻译： 提供了MIF的抑制剂，其可用于治疗各种疾病，包括治疗与MIF活性相关的病理状况。 MIF的抑制剂具有以下结构：
-
-
-
-
-
-
-
-
-
搜索结果
40 条记录 (耗时 0.038 秒)
